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OligonucleotidesThe therapeutic beneﬁt of phosphorothioate oligodeoxynucleotides (PS-ODN) containing immune stim-
ulatory sequences has been demonstrated in animal models of cancer and infection. Several tools are
available for the determination of these oligonucleotides in biological samples and pharmaceutical
preparations, including UV spectroscopy, dye binding, isotopic tracing, capillary gel electrophoresis
(CGE), hybridization-based enzyme-linked immunosorbent assay (ELISA), and chromatography tech-
niques.
However, due to inter-assay variability and accuracy problems associated with the afore mentioned
methods, we have developed and validated an isocratic high performance liquid chromatographic
(HPLC) for analytical determination of PS-ODN containing unmethylated CpG motifs (CpG-ODN).
Validation under Food and Drug Administration (FDA) guidelines of the analytical parameters include:
linearity (r2 0.9996), LOD (0.86 lg/ml) and LOQ (6.25 lg/ml), intra (0.19–3.37%) and inter-day precision
(0.63–3.75%) expressed as relative standard deviation (RSD), and robustness parameters (less than
2.80%). Using this method, recoveries ranging from 89.9% to 99.9% were obtained. Thus, this method pro-
vides a simple, sensitive, precise and reproducible examination which can be readily adapted for the
assessment of CpG-ODN in different pharmaceutical preparations.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Phosphorothioate oligodeoxynucleotides (PS-ODN) containing
unmethylated CpG motifs (CpG-ODN) have been developed as a
novel ﬁrst generation drug candidate for immune therapy in cancer
and are currently in Phase I–III human clinical trials in non-small
cell lung cancer, melanoma and cutaneous T cell lymphoma [1].
These are molecules stabilized by substituting non bridging oxygen
with sulphur atoms to form a phosphorothioate backbone (Fig. 1)
[2].
Since CpG-ODN are inherently prone to rapid degradation by
nucleases which renders them inactive in the free form, the use
of these chemical modiﬁcations have effectively reduced the
sensitivity of ODNs to nuclease, prolonged circulation lifetime
and improve their pharmacological/toxicological properties [3].Nevertheless, the use of free CpG-ODN still faces several signiﬁ-
cant challenges including unfavorable pharmacokinetics, a lack of
speciﬁcity for target cells and poor cellular uptake [4]. For this rea-
son, numerous strategies have been developed in order to design
and characterize novel carriers for these kinds of molecules [5].
Regarding this aspect, we have studied a variety of supramolecu-
lar aggregates formed by self-assembly of ascorbic acid derivatives,
namely ascorbyl palmitate (ASC16) [6]. On cooling, this compound
inwater systemsgives liquidcrystals (calledcoagels)which,oncool-
ing, becomes gels with lamellar structure. In previous works, we
have explored such systems as carriers for CpG-ODN [7], speciﬁcally
the coagel formed from ASC16 self-assembly (Coa-ASC16). Due to
the complexity of the phase equilibrium observed in these lyotropic
liquid crystalline systems [8], the evaluation of the bio-
pharmaceutical performance of these novel formulations requires
the development of adequate analytical methodologies.
Different bioanalytical methods to assay oligodeoxynucleotides
with a PS backbone have been reported, such as UV spectroscopy,
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Fig. 1. Representative structure of CpG-motif showing functional groups on
cytosine and guanine.
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(CGE) [10], hybridization-based enzyme-linked immunosorbent
assay (ELISA) [11], and chromatography techniques [12].
The accuracy of an absorbance measurement may be unreliable
since it is based on the unconﬁrmed assumption that the DNA is
pure and entirely in a double-stranded or single-stranded form.
Dye-binding assays in general are subject to interferences and sur-
factants represent one of the most important. Postlabeling is lim-
ited both by its reliance on a radioisotope, and on the
assumption, which is not convenient to test, that the yield of radio
enzymatic step is 100% [13].
Although segregating techniques, including CGE were devel-
oped to separate PS-ODN from their interfering metabolites, their
efﬁcacy was limited by the low reproducibility caused by endoge-
nous interference as well as cumbersome sample preparation [14].
Regarding ELISA, they have high sensitivity and could be used in
the terminal phase of pharmacokinetics assessment, but these
methods cannot distinguish full-length PS-ODN from their
metabolites, which may cause cross-hybridization and the over-
estimation of the parent drug [15].
One common problem in developing an HPLC method for quan-
titative PS-ODN determinations is the extensive sample clean-up
required. More recently, one-step solid-phase extractions (SPE)
have been described in conjunction with liquid chromatography-
mass spectrometry (LC/MS), but a major limitation of these meth-
ods is the low extraction recovery.
Taking into account these considerations, the aim of this study
was to develop and validate a fast, reliable, selective and economic
HPLC method able to quantify minimal CpG-ODN concentrations in
different pharmaceutical systems. This article also includes results
concerning to the effect of assay conditions over the stability of
CpG-ODN and the protective effect that coagel could exert on
CpG-ODN stability against enzymatic activity of exonucleases.2. Methods
2.1. Chemicals and reagents
The CpG-ODN (sequence 50-TCCATGACGTTCCTGACGTT-30,
phosphorothioate backbone) was purchased from Operon
Technologies Inc. (Alameda, California, USA) and 6-O-ascorbyl
palmitate (ASC16) was purchased from Fluka Analytical (Milan,
Italy). Buffer tris(hydroxymethyl)aminomethane (Tris-HCl) was
obtained from Biopack (Buenos Aires, Argentina). Acetonitrile
(ACN), triethylamine (TEA) and acetic acid (AA) were all HPLC-
grade and acquired from Sintorgan (Buenos Aires, Argentina).Puriﬁed water namely milli-Q water was obtained from Merck
Millipore (Billerica, Massachusetts, USA).2.2. Equipment and software
The HPLC analysis was carried out in an Agilent Technologies
Series 1100 apparatus (Waldbronn, Germany) equipped with a bin-
ary pump, an auto sampler tray with column compartments, and a
UV-Vis detector (kmax absorbance 261 nm). Instrumental control
and chromatographic data acquisition were performed with
Agilent ChemStation Rev. B.03.01 software (Waldbronn,
Germany). A Mettler Toledo DG 115-SC (Columbus, Ohio, USA)
equipped with a combined Ag/AgCl/glass electrode was used to
measure the experimental pH of the solutions.2.3. Chromatographic conditions
The analytical column was a reversed phase C18 (250  4.6 mm
i.d., 5 lm particle size) Phenomenex TM (Torrance, California,
USA) protected by a Security Guard Phenomenex TM precolumn
(Torrance, California, USA). Elution was performed isocratically at
25 C at a ﬂow-rate of 0.7 mL min1. The mobile phase was ﬁltered
through a 0.45 lm pore size ﬁlter (Merck Millipore, Billerica,
Massachusetts, USA) and degassed by vacuum prior to use.2.4. Mobile phase and standard solutions preparation
A stock solution of CpG-ODN was prepared by reconstitution of
CpG-ODN in saline solution (NaCl 0.9%) to reach a ﬁnal concentra-
tion of 1000 lg mL1. This solution was stored at 20 C.
Standard solutions were prepared by diluting different aliquots
of the stock solution in buffer Tris-HCl pH 7.2. Next, the samples
were ﬁltered through a 0.22 lm pore size ﬁlter (Merck
Millipore, Billerica, Massachusetts, USA), transferred into auto
sampler vials and injected (20 lL) into the HPLC system.
The mobile phase was prepared by measuring 5.70 mL of AA
and 13.90 mL of TEA and mixed with Milli-Q water to reach a ﬁnal
concentration of 0.1 M in triethylammonium acetate buffer (TEAA).
Subsequently, the pH was adjusted to 7 with AA. The ﬁnal com-
position of mobile phase was buffer: acetonitrile (50/50).2.5. Preparation of CpG-ODN loaded coagels (Coa-ASC16)
The samples were prepared by mixing the components (Asc16,
water, and CpG-ODN) in the appropriate proportions in closed
glass tubes. The dispersions were heated up to 72 C and then
homogenized in an ultrasonic bath for 15 min at 72 C and left to
reach room temperature in small, hermetically closed plastic tubes
and stored in darkness until measurement. Samples were prepared
to reach a ﬁnal concentration of 0.02% and 1% weight/weight (w/w)
fractions of ASC16 and CpG-ODN, respectively.2.6. Nuclease stability of CpG-ODN load into Coa-ASC16
In order to evaluate the effect induced by Coa-ASC16 on
CpG-ODN stability, we performed a nuclease digestion assay.
CpG-ODN or CpG-ODN load into coagels (CpG-ODN/Coa-ASC16)
samples were exposed to a 30-exonuclease I enzyme solution
(Thermo Fisher Scientiﬁc Inc., Waltham, Massachusetts, USA)
prepared according to manufacturer speciﬁcations and incubated
at 37 C. The CpG-ODN remaining at each time point was
quantiﬁed by the HPLC technique.
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3.1. Optimization of experimental conditions
In order to ﬁnd the best composition of the mobile phase that
allows the analysis of CpG-ODN alone and load into Coa-ASC16,
each compound separately was injected in mobile phases at pH 7
containing TEAA buffer and ACN at the following ratio: 90/10;
80/20; 70/30; 60/40; 50/50; 40/60;30/70; 20/80; 90/10.
In the case of mobile phases with high polarity, e.g., 20/80 and
80/20, the overlapping of some signals was observed, whereas an
intermediate polarity allowed the molecule of interest to be eluted
with a convenient peak resolution. Following the criteria of maxi-
mum resolution – minimum analysis time, TEAA buffer: ACN (50/
50) was selected as the most suitable mobile phase for the quan-
tiﬁcation of CpG-ODN.
In these experimental conditions, chromatographic parameters
such as capacity factor (k), and resolution (Rs) were 2.3 and 4,
respectively.
At ﬂow rates greater than 1 mL min1 the retention time for
CpG-ODN was shorter than 1.5 min, which resulted in the super-
position of peaks corresponding to test and solvent samples. On
the other hand, ﬂow rates smaller than 0.5 mL min1 resulted in
non-acceptable peak resolution. Hence, the ﬂow rate was set at
0.7 mL min1. In the optimized conditions, acceptable retention
time of around 2.6 min was observed for CpG-ODN.
Fig. 2 shows the chromatogram obtained after the injection of
CpG-ODN loaded in Coa-ASC16 (prepared as described in
Section 2.5.) and diluted with mobile phase prior to injection.
High resolution (Rs > 1.5) was obtained for CpG-ODN in spite of
the complexity of the system (CpG-ODN + Coa-ASC16) and the
non-speciﬁcity of the selected column for oligonucleotides
quantiﬁcations.
In the method reported here, we have achieved comparable
results in terms of chromatographic parameters in comparison to
those reported using more complex and expensive techniques
[16]. In addition, neither solid-phase extraction method nor
oligonucleotides precipitation techniques were required.
Moreover, the tailing factors for CpG-ODN were within an accept-
able range since good peak symmetry and resolutionwere achieved.
3.2. Validation method
This methodology has been validated according to the FDA val-
idation guidance [17] in terms of linearity, limits of detectionTime (min)
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Fig. 2. Typical HPLC chromatogram of a standard sample preparation containing
CpG-ODN loaded into Coa-ASC16. CpG-ODN retention time is 2.6 min. Refer to text
for HPLC conditions.(LOD) and quantiﬁcation (LOQ), precision and accuracy, selectivity,
recovery and robustness.
3.2.1. Calibration parameters, limits of detection (LOD) and
quantiﬁcation (LOQ)
A series of standard curves were assayed over a concentration
range of 6.25–375 lg mL1. Triplicates of seven points from three
calibration curves were analysed every 3 days for 2 weeks. The
data of correlation between peak areas versus drug concentration
was statically processed by linear least square regression analysis.
The lineal regression data for calibration plots (n = 3) showed a
good linear relationship over the range of concentration evaluated.
The coefﬁcient of correlation was 0.9988, with slope and intercept
values of 54161.33 ± 53.14 and 168.28 ± 6.90, respectively. No sig-
niﬁcant difference was observed in the slopes of standard curves
(ANOVA p > 0.05).
The limit of quantiﬁcation (LOQ) was considered as the lowest
standard concentration in the analytical run affording accuracy
and precision 620% and in this method it was 6.25 lg mL1.
The limit of detection (LOD) was calculated with the 3 s criter-
ion (three times the standard deviation of the lowest concentration
solution included in the calibration divided by the slope of the cali-
bration curve) [18] using a series of 7 solutions and its value was
0.866 ± 0.017 lg mL1.
3.2.2. Intra- and inter-day precision and accuracy
The accuracy and precision of the method were determined by
triplicate analysis of sets of three quality control (QC) standards at
concentrations of 250 lg mL1 (QC-high), 125 lg mL1 (QC-inter-
mediate) and 50 lg mL1 (QC-low). The intra-day precision was
determined by injecting these three test solutions seven times on
the same day. The inter-day precision determination involves the
average of seven measurements of the intra-day precision values
taken on ten days over a 2-month period.
Table 1 represents the results expressed as the percentage of
the relative standard deviation and relative error (RSD, %) or coef-
ﬁcient of variation (CV) for the intra- and inter-day values.
Reproducibility methods were acceptable since the CVs for the
QC over the analytical range was <3.75% for intra- and inter-day
precision assays. These results endorse the potential utility of the
proposed method for the analysis of this compound in Coa-
ASC16 formulations. Thus, the procedure developed can be used
in the quality control, routine analyses and stability studies of
CpG-ODN.
3.2.3. Recovery studies
In a new series of experiments, the QC-high and QC-low solu-
tions (seven replicates for each standard) were spiked in Coa-
ASC16 matrices, and the CpG-ODN amount previously diluted in
mobile phase was measured. Standard solutions were processedTable 1
Precision and accuracy of the HPLC assay for CpG-ODN in Coa-ASC16.
Nominal
concentration
(lg mL1)
Calculated concentration
(mean ± SD) (lg mL1)
Precision
R.S.D. (%)
Accuracy
(%)
Intra-day evaluation
QC-high-250 247.38±4.14 1.66 98.95
QC-intermediate-125 111.29±4.61 3.37 90.66
QC-low-50 46.89±0.01 0.19 93.78
Inter-day evaluation
QC-high-250 248.45±6.88 2.75 99.38
QC-intermediate-125 111.06±4.70 3.75 90.36
QC-low-50 48.16±0.31 0.63 96.32
S.D.: standard deviation; n = 7 (number of replicates).
Ln
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(analytical) recovery was calculated by comparing the concentra-
tion obtained from the standard solution with the actual added
amounts. The data obtained shows satisfactory recoveries for
CpG-ODN (First row, Table 2).
It is not mandatory to recover 100% of the analyte, but the
extent of recovery of it should be consistent, precise, and
reproducible.
Regarding this, the recovery of CpG-ODN was tested in samples
conserved at room temperature for 5 h (normal run time for each
batch) and in those frozen at 20 C for 8 weeks. The samples were
analysed immediately after the storage period. As it is shown in
Table 2, the recovery results after the long-term and the short-term
storage conditions were also satisfactory.Time (h)
0 1 2 3 4 5
-5
obs 1/2
Fig. 3. Kinetics of pseudo-ﬁrst order degradation of CpG-ODN and CpG-ODN/Coa-
ASC16 in aqueous solutions of exonuclease enzyme.3.2.4. Robustness
The robustness of the method was examined by replicate injec-
tions (n = 5) of 50 lg mL1 and 100 lg mL1 standard solutions
with slight modiﬁcations on the chromatographic parameters (buf-
fer concentration, temperature, and ﬂow rate). The R.S.D. (%)
obtained after changing the retention time and peak area was cal-
culated, being less than 2.80% (Table 3). In conclusion, variations in
all the studied parameters had no signiﬁcant effects on retention
time or peak area, and the developed method proved to be robust
for CpG-ODN quantiﬁcations.3.3. Application of the HPLC method to nuclease digestion assays of
CpG-ODN and CpG-ODN load into ascorbyl palmitate coagels
In order to challenge the performance of the HPLC technique,
this method was used as an analytical tool to perform a stabilityTable 2
Recovery (%) of CpG-ODN from Coa-ASC16 under different conditions.
QC-high (n = 7) QC-low (n = 7)
Recovery (%) RSD (%) Recovery (%) RSD (%)
Normal conditions 97.63 3.90 99.90 1.70
20 C (8 weeks) 89.93 3.56 98.83 5.55
RT (5 h) 95.61 3.26 96.24 2.30
Table 3
Robustness evaluation of the HPLC method.
Chromatographic changes CpG-ODN
(100 lg mL1)
CpG-ODN
(50 lg mL1)
tR (min) Area tR (min) Area
Buffer TAA conc. (M)
0.1 2.78 5796.36 2.84 2578.00
0.05 2.88 6004.21 2.81 2633.16
Mean 2.83 5900.29 2.83 2605.58
SD 0.07 146.97 0.02 39.00
RSD (%) 2.50 2.49 0.75 1.50
Temperature (C)
25 2.80 5629.22 2.80 2595.30
35 2.82 5410.42 2.86 2550.69
Mean 2.81 5519.82 2.83 2573.00
SD 0.01 154.71 0.04 31.54
RSD (%) 0.50 2.80 1.50 1.23
Flow rate (mL min1)
0.6 2.85 5300.00 2.85 2760.23
0.7 2.80 5500.00 2.83 2895.27
0.8 2.70 5480.00 2.73 2785.00
Mean 2.75 5490.00 2.78 2840.14
SD 0.08 110.15 0.06 71.89
RSD (%) 2.78 2.01 2.31 2.53assay of CpG-ODN against exonucleases. It is well known that
nucleotide cleavage by exonucleases is the major degradation
pathway of CpG-ODN and it occurs primarily from the 30 end
[19].
As shown in Fig. 3, degradation of CpG-ODN follows a pseudo
ﬁrst order kinetics with a Kobs of 0.54 h1 and a half-life of
1.27 h. When the same compound was formulated into the coagel,
the half-life increased almost twice and it was observed a decrease
in the degradation constant, which could result in an increase of its
stability against degradation by exonucleases attributable to a pro-
tective effect of this carrier.
Based on these results, the enhancer effect of Coa-ASC16 on
CpG-ODN adjuvant activity reported before [7] may be given, in
part, by the effect of protection from degradation by nucleases.
Thus, the use of Coa-ASC16 as strategy for delivering the CpG-
ODN may therefore represent a valuable approach to protect them
from nuclease degradation in future vaccination trials.4. Conclusion
This paper describes a rapid and reproducible HPLC method
which enables the determination of CpG-ODN in in vitro condi-
tions. A simple and available chromatographic buffer system,
with an usual C18 column was utilized for the validation process.
The relatively short retention times facilitates the analysis of a
large number of samples over a short period of time. Therefore,
the HPLC method developed here shows good sensitivity and
selectivity, and it is suitable for reliable determination of CpG-
ODN.
Moreover, this method does not require complex procedures
such as sample extraction and/or sample cleaning, and does not
require large volumes of samples and solvents. Results indicate
that the procedure described here is useful for the quantiﬁcation
of this compound loaded into Coa-ASC16 and the evaluation of
its stability against exonuclease enzyme digestion.Acknowledgments
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